<DOC>
	<DOCNO>NCT00690365</DOCNO>
	<brief_summary>This single-arm , phase IV , open-label , prospective , non interventional study approximately 600 patient follow 6 month order evaluate safety efficacy quetiapine . Patients switch 4 7 day cross-titration period previous antipsychotic medication quetiapine accord approve SPC .</brief_summary>
	<brief_title>Safety Efficacy Switching Quetiapine Outpatients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Diagnosis schizophrenia least 1 year prior screen Inadequate response poor safety /tolerability noncompliance previous antipsychotic medication Provision Informed Consent prior enrolment Known hypersensitivity active substance excipients Patients receive P450 3A4 inhibitor Pregnancy lactation Substance abuse dependence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Switching</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>unsuccessfully treat</keyword>
	<keyword>antipsychotic</keyword>
</DOC>